Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dova Pharmaceuticals, Inc.

http://www.dova.com

Latest From Dova Pharmaceuticals, Inc.

Sobi's Doptelet Launch In EU To Drive Transformation

Sobi is launching the thrombocytopenia drug Doptelet in Europe after acquiring the originator, Dova Pharmaceuticals, and expects to capture significant market share from older products while adding to its business in rare diseases, hematology, and immunology.

Blood & Coagulation Disorders Launches

Sobi’s Doptelet Disappoints In Large New Indication

A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations. 

Clinical Trials Companies

Verona Stock Soars After $200m Placement For COPD Drug

The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.

Financing Respiratory

Verona Details COPD Opportunity For Ensifentrine

Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.

Clinical Trials Respiratory
See All

Company Information

  • Other Names / Subsidiaries
    • AkaRx, Inc.
    • PBM Capital Group
UsernamePublicRestriction

Register